In this commentary, Ian W. Flinn, MD, PhD, provides expert answers to frequently asked questions on the use of BTK inhibitors in the management of patients with CLL.
In this commentary, experts answered clinician questions on first-line treatment of CLL, including the use of targeted therapies and FCR, the risk of COVID-19 infection with different regimens, and management of autoimmune manifestations.
Use this Interactive Decision Support Tool to see strategies to assess and manage adverse events associated with BTK inhibitors from 5 experts in managing patients with hematologic malignancies.
Download this slideset from Ian Flinn, MD, PhD to review the rational and overview of the data on the use of BTK inhibitors for patients with CLL.
Download this slideset from Ian W. Flinn, MD, PhD and Susan M. O’Brien, MD for the most recent data selecting first-line therapy for patients with CLL, including differences in treatment selection for patients with or without del(17p) or TP53 mutations.
Download this slideset from John Pagel, MD, PhD for the most up-to-date data on therapy for patients with R/R CLL, including novel approaches that may impact clinical practice in the near future.
Download this short summary slideset of key takeaways from a live CCO Webinar focused on key data for using BTK inhibitors in patients with CLL.
Watch this on-demand Webcast capturing a live CCO Webinar to learn more about the latest data on BTK inhibitors and how to integrate them into your clinical practice for optimal treatment of patients with CLL.